It is well-known that AKI can arise in various pathological conditions, such as drugs, toxicants, ischemia/reperfusion (I/R), obstruction, or sepsis, resulting in acute tubular necrosis (Ronco et al., 2019)
Preclinical studies using metabolic assays such as euglycemic clamp techniques indicate that AOD 9604 does not impair insulin-mediated glucose uptake in adipose or peripheral tissues
Studies typically use once-daily administration , often morning on empty stomach before activity to maximise the lipolytic window
These proteins comprised immunoglobulins (Igs), C4BPA, RNASE3, CTSG, AZU1, ELANE, PRTN3, S100A9, DEFA3, FGA, and others
Optimized approach: Inject Lipo-C 30-60 minutes before morning fasted cardio
Instead, the findings point to patterns that may warrant further investigation